Road and parking lot construction in Madison, Wis. may result in travel delays and route changes to UW Health clinic and hospital locations. Please plan accordingly.Read more
American Family Children’s Hospital only place for localized intra-arterial chemotherapy in Wisconsin
Madison, Wis. – Last month, two clinicians were part of a team that introduced a new chemotherapy technique at American Family Children’s Hospital to treat a patient with retinoblastoma, the most common type of eye cancer in children.
Dr. Margo Hoover-Regan, pediatric oncologist and clinical director of the Pediatric Hematology and Oncology Program, UW Health Kids, and associate professor, University of Wisconsin School of Medicine and Public Health, and Dr. Sudarshawn Damodharan, pediatric hematology/oncology fellow, UW Health, employed intra-arterial chemotherapy (IAC) to deliver anti-tumor drugs directly to the tumor bed in the retina.
“In the past, retinoblastoma treatments have included enucleation, or removal of the eye, radiation, and systemic chemotherapy,” Damodharan said. “Intra-arterial chemotherapy is superior to those methods in some cases.”
First developed in Japan, and also known as superselective ophthalmic artery chemotherapy, IAC allows clinicians to deliver a higher concentration of chemotherapeutic drugs with great precision through a catheter from the femoral artery into the ophthalmic artery ostium. IAC typically requires two treatments over two months, with an examination by the ophthalmologist under anesthesia to determine effectiveness. In most cases, there is full remission, and the eye is saved, Damodharan said.
An uncommon but serious childhood cancer, retinoblastoma arises as a tumor in the retina, accounting for 3 percent of cancers in children younger than 15 years of age. Most cases, however, are diagnosed before 2 years of age. The National Cancer Institute estimates the annual incidence among children younger than 4 years old to be 1 in 14,000 to 18,000; about 200 to 300 cases annually in the United States.
“We are now set up to take on most retinoblastoma cases in the Midwest,” Hoover-Regan said, “and American Family Children’s Hospital is at the forefront of retinoblastoma treatment.”
Retinoblastoma is caused by a genetic mutation. If the mutation is carried by the parents, it will likely affect both eyes of the child. In cases when the mutation was not passed down from the parents, only one eye may be involved.
It is often diagnosed early; newborns are typically checked for a “red reflex” when a light is shone into the eye. After the newborn period, a pediatrician’s routine eye exam may show the back of the eye appearing white rather than red if retinoblastoma is present. Early treatment is essential to save the eye and avoid later involvement of the central nervous system and other organs.
Although it is a relatively rare cancer, retinoblastoma serves as a benchmark and exemplar in oncology treatment. It was the first human cancer to be treated in the 1920s and has evolved from having a nearly 100 percent mortality rate to a survival rate of more than 98 percent in developed countries.
A greater understanding of its genetic origins and substantial progress in treatment options account for this remarkable improvement, according to Hoover-Regan.